Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 119 participants.

Also called NCT05613426

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 119 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05613426
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05613426. Randomized; single masking; primary purpose treatment. Start 2023-04-03 (actual); primary completion 2025-07-16 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI
Acronym
EVALUATE-STEMI
Condition
ST Elevation Myocardial Infarction (STEMI)
Intervention (Drug)
Rosuvastatin 20 mg
Intervention (Drug)
Evolocumab 140 mg/1 ml Subcutaneous Solution [REPATHA]
Lead sponsor
Henan Institute of Cardiovascular Epidemiology (class: other)

Record details

Record id
cardio:ct-nct05613426
Content hash
0165a4792f2dd5d9d20169b1b455602b82604b10e6bcfa968191f53cba11618f